Jim Sullivan, Ph.D.

Bio

Jim joined OrbiMed as a Venture Partner in 2019.  He is also the CEO of a portfolio company, Vanqua Bio, which is focused on the development of novel therapeutic agents for neurological conditions including Parkinson’s disease. Previously, he was the Vice President of Research at AbbVie where he was responsible for AbbVie’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C, and cystic fibrosis. Jim has advanced more than 100 compounds into clinical development across several disease states and technology platforms. These include products on the market for HCV (Mavyret and Viekira), the-first-in- class Bcl2 selective inhibitor, Venclexta, for hematological cancers, Rinvoq, an oral agent for patients with autoimmune diseases, and multiple compounds currently in Phase II or III clinical trials. He has authored/co-authored more than 130 scientific publications and is an inventor on 11 patents. Jim is an adjunct faculty member at Northwestern University and serves on the board of several companies and foundations including Aliada. He earned his bachelor’s degree and Ph.D. in biochemistry from Trinity College Dublin and conducted post-doctoral research in neurobiology at Northwestern University. Outside of work, Jim enjoys playing golf, biking, and Notre Dame football.